STEM CELL THERAPEUTIC

What is “CARTISTEM” used for treatment of Hiddink?

‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency

Selected as a conducting company of ‘global high-tech biomedicine industry’

MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’

US ‘Stem cells regenerative medicine congress’ invites MEDIPOST for the first time as a Korean company

MEDIPOST, achieves ‘150 patent applications and 50 patent registrations’

Core dementia treatment technology patented at 6 European countries, concurrently

‘CARTISTEM’ shows superb results from 3 year long term tracking clinical trials

Lung disease medicine, ‘PNEUMOSTEM’ was designated as ‘Orphan Drug’ in Europe

‘CARTISTEM’ injection to U.S. clinical trial subject completed

U.S. ABC News gave intensified coverage on ‘CARTISTEM’

Participation in Biotec Japan and local publicity activities on CARTISTEM